Acta dermato-venereologica最新文献

{"title":"Quality of Life, Mental Health and Executive Function in Individuals with Basal Cell Naevus Syndrome.","authors":"Karianne H Brandtzæg, Charlotte Von der Lippe, Ina S Almdahl, Anvor Rossow, Ragnhild S Falk, Petter Gjersvik, Kristin H Hortemo, Solrun Sigurdardottir","doi":"10.2340/actadv.v106.adv-2026-0335","DOIUrl":"10.2340/actadv.v106.adv-2026-0335","url":null,"abstract":"<p><p>Basal cell naevus syndrome (BCNS) is a rare genetic disorder characteriszed by multiple basal cell carcinomas, as well as different extracutaneous tumours, cysts and abnormalities. Research on health-related quality of life (HRQoL) and mental health in BCNS is limited. This cross-sectional study included 62 individuals ≥18 years diagnosed with BCNS. Clinical and genetic data were collected, and five5 validated questionnaires were used to assess self-reported HRQoL, psychological distress, fatigue, pain and everyday executive functioning. Median regression analyses were conducted to identify factors associated with HRQoL. Independent samples t-tests and one proportion z-tests were conducted to compare the BCNS group with the general population. Individuals with BCNS reported lower HRQoL compared with the general population. Elevated anxiety symptoms were observed in 14 individuals (24%). The proportion of individuals reporting everyday executive deficits was higher in the BCNS group compared with the general population. Engagement in employment or higher education was associated with better physical and mental HRQoL, whereas symptoms of anxiety and everyday executive deficits were associated with reduced mental HRQoL. Findings highlight mental health challenges in BCNS. Routine screening for anxiety and executive functioning is suggested as essential steps in identifying those at risk and provideproviding timely psychological support.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13459420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148704819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.","authors":"John Su, Andreas Wollenberg, Melanie Funk, Tina Mesarič, Brandon Hu, Tammi Shipowick, Kelly Barta, Kristin Belleson, Li-Chuen Wong, Kiu Han Kim, Chia-Yu Chu, Sandipan Dhar, Yoshiyuki Kataoka, Kin Fon Leong, Kam Lun Ellis Hon, Erere Otrofanowei, Peter Foley, Lin Ma, Yong Kwang Tay, Marie Lodén, Anousha Yazdabadi, Kathrin A Gibson, Jonathan D Akikusa, Andrew Östör, Connie Katelaris, Frank Thien, Michihiro Futamura, Rie Yotsu, Peter Schmid-Grendelmeier, Alain Taïeb","doi":"10.2340/actadv.v106.10.2340/adv-2026-0868","DOIUrl":"10.2340/actadv.v106.10.2340/adv-2026-0868","url":null,"abstract":"<p><p>Treat-to-target strategies link predefined goals to regular assessment and treatment adaptation. In atopic dermatitis, recent initiatives have mainly defined thresholds using clinician- and patient-reported outcomes. This review and position paper critically examines current approaches and proposes priorities for a more clinically meaningful, patient-centred and globally applicable framework. It synthesizes recent consensus and outcome-harmonization initiatives with selected lessons from rheumatoid arthritis and asthma and was informed by multidisciplinary, patient-inclusive discussions at an International Society of Atopic Dermatitis-World Health Organization premeeting. The workshop was not a Delphi or formal consensus exercise; it was used to identify conceptual priorities and implementation challenges for future international consensus work. Current proposals converge partly around severity thresholds and symptom control but insufficiently capture disease instability, comorbidities, family burden, treatment burden and real-world constraints. We propose 4 complementary domains: disease activity; symptoms and function; global patient health and disease impact and longitudinal control and treatment adaptation. Some components are supported by validated measures, whereas others remain exploratory. Treat-to-target in atopic dermatitis should evolve beyond isolated thresholds towards an adaptable multidimensional strategy, followed by formal international consensus and prospective validation.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13459419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148704788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Metoprolol: Resolution via Beta-blocker Switch.","authors":"Tim Schricker, Nikolaus Möhlenkamp, Franziska Hübner, Ulrike Raap, Nikolaos Patsinakidis","doi":"10.2340/actadv.v106.adv-2026-0743","DOIUrl":"10.2340/actadv.v106.adv-2026-0743","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13455170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Phenotyping of Atopic Dermatitis Using Combined Global Severity (POEM) and Facial Burden (BoFA): A French Population-based Observational Study.","authors":"Jean Michel Amici, Marie Sylvie Doutre, Bruno Halioua, Audrey Bourne Chastel, Stéphanie Merhand, Charles Taieb, Delphine Staumont","doi":"10.2340/actadv.v106.adv-2026-0622","DOIUrl":"10.2340/actadv.v106.adv-2026-0622","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is characterized by substantial clinical heterogeneity. Global severity is typically assessed using scores such as the POEM; however, lesion localization -- particularly on the face -- may generate psychosocial consequences partly independent of overall disease severity. This cross-sectional observational study (VISEABLE) included 1,400 French adults with physician-confirmed AD. Severity was measured using the POEM (Clear/Almost Clear: 0-7 vs. Moderate-severe: ≥8) and facial involvement using the BoFA (0-109; threshold=36, population median). Six phenotypes were defined through a 2×3 combination. The POEM and BoFA correlation was moderate (r=0.365; ρ=0.389; p<0.001). Phenotype Ph3 (Clear/Almost Clear POEM / Severe facial involvement, n=58) exhibited stigmatization scores (PUSH-d=21.93) and life trajectory impact (DLLIM=14.76) not significantly different from Ph4 (Moderate-severe POEM / No facial involvement, n=527; p>0.25 for all comparisons). In multiple regression analysis restricted to patients with facial involvement, BoFA was the dominant independent predictor of stigmatization (β=11.44, p<0.001; partial R²=46.2 %; overall R²=0.532), superseding POEM (p=0.076, ns; partial R²=0.6%). Mild eczema with severe facial involvement generates a psychosocial burden comparable to that of moderate-to-severe eczema without facial involvement. Systematic BoFA assessment is essential in all patients with AD.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13455168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab for Treatment-refractory Bullous Pemphigoid: A Case Series of Six Patients.","authors":"Catalina Hartmann Skovsgård, Kimia Kheirmand, Toke Touborg, Christian Vestergaard, Rikke Bech","doi":"10.2340/actadv.v106.adv-2026-0537","DOIUrl":"10.2340/actadv.v106.adv-2026-0537","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13446090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymptomatic Multiple Nodules on the Back: A Quiz.","authors":"Yingying Xiang, Chunfang Zhang, Jian Li, Hong Ren, Xiao Tan, Renqiong Chen","doi":"10.2340/actadv.v106.adv-2026-0578","DOIUrl":"10.2340/actadv.v106.adv-2026-0578","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13446089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry.","authors":"Stephan Traidl, Angela Cornelius, Luise Heinrich, Doreen Siegels, Helena Zacharias, Annice Heratizadeh, Tatjana Honstein, Barbara Kind, Dora Stölzl, Matthias Augustin, Thomas Schaefer, Anne Bong, Susanne Abraham, Andreas Pinter, Jutta Ramaker-Brunke, Michael Schulz-Kiesow, Sven Quist, Beate Schwarz, Tilo Biedermann, Mohammad Asefi, Caroline Mann, Nicole Adler, Michael Sticherling, Knut Schäkel, Anke Herrmann, Kathrin Meinhardt, Maren Stahl, Christiane Handrick, Sabine Anders, Stephan Weidinger, Jochen Schmitt, Thomas Werfel","doi":"10.2340/actadv.v106.adv-2026-0616","DOIUrl":"10.2340/actadv.v106.adv-2026-0616","url":null,"abstract":"<p><p>Atopic dermatitis is commonly associated with depressive symptoms and fatigue, which significantly impact quality of life. While clinical trials suggest beneficial effects of dupilumab on mental health, real-world evidence remains limited. This longitudinal cohort study analysed data from adult patients treated with dupilumab in the TREATgermany registry. Subgroups were defined by baseline Center for Epidemiologic Studies Depression Scale (CES D) scores ≥16 (clinically significant depressive symptoms) and Fatigue Severity Scale (FSS) scores >4 (significant fatigue). Clinical severity (Eczema Area and Severity Index [EASI], objective Scoring Atopic Dermatitis [oSCORAD]), quality of life (DLQI), psychological symptoms, treatment needs and benefits (PNQ, PBI) and drug survival were assessed over 12 months. Among 633 patients, those with elevated baseline CES-D (n=309) or FSS (n=281) scores reported greater disease burden measured by DLQI, while EASI and oSCORAD did not differ between subgroups. Both CES-D and FSS scores decreased markedly within the first 3 months. Sleep and social functioning needs were more frequently reported in high-burden subgroups and more often fulfilled after 12 months. Drug survival was comparable across subgroups. Dupilumab treatment was associated with significant improvements in depressive symptoms, fatigue and skin severity. Patients with higher baseline mental health burden showed comparable improvements in patient relevant domains, supporting the broad relevance of dupilumab in real-world atopic dermatitis care.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13446091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CK20- and Virus-negative Merkel Cell Carcinoma with Complete RB1 Loss and TP53/ APC Truncations.","authors":"Motoki Hada, Hiroyuki Morisaka, Yutaka Matsumura, Yosuke Ishitsuka, Manabu Fujimoto","doi":"10.2340/actadv.v106.adv-2026-0514","DOIUrl":"10.2340/actadv.v106.adv-2026-0514","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Clinical Response Predicts Treatment Persistence in Advanced Therapy-naive Atopic Dermatitis.","authors":"José Javier Martínez-Simón, Lucía Carrasco-Piernavieja, Estefanía Zhan Zhou, Marta Isabel Andreu-Barasoain, Araceli Sánchez-Gilo, Elena García-Zamora, Virginia Collados-Arroyo, Montserrat Pérez-Encinas, Francisco Javier Vicente-Martín, José Luis López-Estebaranz","doi":"10.2340/actadv.v106.adv-2026-0778","DOIUrl":"10.2340/actadv.v106.adv-2026-0778","url":null,"abstract":"<p><p>Treatment persistence is a key real-world outcome integrating effectiveness and tolerability in moderate-to-severe atopic dermatitis (AD). We conducted a retrospective multicentre cohort study in 146 advanced therapy-naïve patients with moderate-to-severe AD initiating dupilumab, anti IL-13 agents or JAK inhibitors (JAKi) between April 2022 and April 2025 at 2 secondary-care hospitals in Madrid, Spain. Overall persistence rates were 82.9%, 69.8%, 59.5% and 54.5% at 6, 12, 18 and 24 months, respectively, with significant differences across therapeutic groups (log-rank p=0.025). In multivariable Cox regression, JAKi were associated with higher discontinuation risk compared with dupilumab (HR 1.79; 95% CI 1.05-3.05; p=0.034) and male sex was independently associated with increased discontinuation risk (HR 2.20; 95% CI 1.27-3.81; p=0.005). Early clinical response at week 16 was the strongest predictor: each 1% increase in EASI improvement was associated with a 3% reduction in discontinuation risk (HR 0.97; 95% CI 0.96 0.98; p<0.001). A parallel gradient was observed using patient-reported pruritus (NRS), confirming the predictive value of both objective and patient reported measures. Baseline biomarkers were not independently associated with persistence. These findings support week 16 as a clinically meaningful decision point for response-guided treatment evaluation in routine practice.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Metabolomic and Proteomic Profiling of the Mechanisms Underlying the Cumulative Impact of Co-occurring Psychiatric Disorders on Atopic Dermatitis.","authors":"Peizhi Deng, Yiyi Yuyang, Jinron Zeng, Jianyun Lu","doi":"10.2340/actadv.v106.adv-2025-0181","DOIUrl":"10.2340/actadv.v106.adv-2025-0181","url":null,"abstract":"<p><p>Atopic dermatitis (AD) has been linked to psychiatric disorders, but the cumulative contribution of psychiatric multimorbidity to incident AD remains unclear. We integrated genome-wide association study summary statistics with UK Biobank cohort, metabolomic and proteomic data to evaluate genetic relationships, longitudinal associations and putative biological intermediates. High-definition likelihood and bidirectional GSMR assessed shared genetic architecture and directionality. Cox models, multimorbidity counts, weighted composite scores and stratified analyses assessed incident AD, including effect modification by serum vitamin D. Plasma metabolomic and proteomic data were examined using mediation analysis and proteome-wide Mendelian randomization. Genetic liability to 5 psychiatric traits was associated with higher AD risk, whereas reverse AD-to-psychiatric effects were not supported. Psychiatric disorders were prospectively associated with incident AD, with higher risk among participants with co-occurring disorders and higher weighted psychiatric burden. Vitamin D status modified these associations although causality cannot be inferred. A branched-chain amino acid metabolic pattern showed statistically significant but modest mediation (1.04%). Proteomic analyses prioritized HLA-DRA, MMP12, TNFRSF14, and VCAM1 as nonspecific inflammatory proteins associated with AD risk in psychiatric populations. Psychiatric multimorbidity marks a sustained elevation in AD risk, potentially through overlapping inflammatory and metabolic pathways.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"106 ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13434537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}